

RecombiMAb[™] Recombinant Antibodies

Murinized Recombinant Monoclonal Antibodies



bioxcell.com

RecombiMAb[™] Primary Antibodies

RecombiMAb[™] antibodies use mouse or human IgG constant regions instead of the typical rat or hamster IgG constant regions, resulting in reduced immunogenicity in mouse and humanized mouse models. In some syngeneic mouse tumor models, particularly in BALB/c mice, repeated rat or hamster IgG administration can result in complications from hypersensitivity reactions. Using the RecombiMAb[™] antibody instead of wild-type clones may reduce antibody immunogenicity and alleviate hypersensitivity reactions. RecombiMAb[™] antibodies also overcome the limitations of traditionally manufactured antibodies by ensuring high lot-to-lot consistency and data reproducibility across experiments.





RecombiMAb[™] anti- mouse PD-1 (CD279) (D265A) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the RMP1-14-CP151 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The RMP1-14-CP151 values (purple squares) were normalized to the isotype control antibody values (grey circles).

RecombiMAb[™] anti- mouse PD-1 (CD279) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the 29F.1A12-CP159 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The 29F.1A12-CP159 values (purple squares) were normalized to the isotype control antibody values (grey circles).





RecombiMAb[™] anti- mouse PD-1 (CD279) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the RMP1-14-CP157 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The RMP1-14-CP157 values (purple squares) were normalized to the isotype control antibody values (grey circles).

RecombiMAb[™] anti- mouse PD-L1 (B7-H1) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the 10F.9G2-CP168 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The 10F.9G2-CP168 values (purple squares) were normalized to the isotype control antibody values (grey circles).

Antigen	Reactivity	Host / Isotype	Mutation(s)	Application(s)	Clone	Catalog #	lsotype Control
4-1BB	Mouse	Mouse,IgG2a	LALA-PG	in vivo activation of 4-1BB*	LOB12.3-CP038	CP038	CP048
4-1BBL	Mouse	Mouseuse,IgG1	D265A	in vivo 4-1BBL blockade*, ELISA*	TKS-1-CP039	CP039	CP047
4-1BBL	Mouse	Mouse,IgG2a		in vivo 4-1BBL blockade*, ELISA*	TKS-1-CP040	CP040	BP0085
4-1BBL	Mouse	Mouse,IgG2a	LALA-PG	in vivo 4-1BBL blockade*, ELISA*	TKS-1-CP041	CP041	CP048
CD4	Mouse	Mouse,IgG2b		in vivo CD4+ T cell depletion*, FC*, WB*	GK1.5-CP127	CP127	BP0086
CD8	Mouse	Mouse,IgG2b		in vivo CD8+ T cell depletion*, WB*	2.43-CP128	CP128	BP0086
CD8 α	Mouse	Mouse,IgG2a		in vivo CD8+ T cell depletion*, WB*	YTS 169.4-CP134	CP134	BP0085
CD16/CD32	Mouse	Mouse,IgG2a		in vivo Fc receptor blocking*, Fc receptor blocking, IF*, FC*	2.4G2-CP025	CP025	BP0085
CD16/CD32	Mouse	Mouse,IgG2a	LALA-PG	in vivo Fc receptor blocking*, Fc receptor blocking, FC*, IF*	2.4G2-CP026	CP026	CP048
CD28	Mouse	Mouse,IgG2a		in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation*	D665-CP042	CP042	BP0085
CD28	Mouse	Mouse,IgG2a	LALA-PG	in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation*	D665-CP043	CP043	CP048
CD40	Mouse	Mouse,IgG2a		in vivo CD40 activation*, in vitro B cell stimulation/activation*	FGK4.5-CP133	CP133	BP0085
CD40L	Mouse	Mouse,IgG1	D265A	in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, WB*	MR-1-CP032	CP032	CP047
CD40L	Mouse	Mouse,IgG2a		in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, WB*	MR-1-CP033	CP033	BP0085
CD40L	Mouse	Mouse,IgG2a	LALA-PG	in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, WB*	MR-1-CP034	CP034	CP048
CD71 (TfR1)	Mouse	Mouse,IgG2a		in vivo depletion of CD71+ cells*	R17 217.1.3-CP130	CP130	BP0085
CSF1R	Mouse	Mouse,IgG2a		in vivo macrophage depletion*, in vitro CSF1R neutralization*, in vivo monocyte depletion*, FC*, WB*	AFS98-CP131	CP131	BP0085
CTLA-4	Mouse	Mouse,IgG1		in vivo CTLA-4 neutralization*, WB*	9D9-CP006	CP006	BP0083
CTLA-4	Mouse	Mouse,IgG2a		in vivo CTLA-4 neutralization*, WB*	9D9-CP007	CP007	BE0085
CTLA-4	Mouse	Mouse,IgG2a	LALA-PG	in vivo CTLA-4 neutralization*, WB*	9D9-CP008	CP008	CP048
CTLA-4	Mouse	Mouse,IgG1		in vivo CTLA-4 neutralization*, in vitro CTLA-4 neutralization*, WB	9H10-CP146	CP146	BP0083
GITR	Mouse	Mouse,IgG1	D265A	in vivo GITR stimulation*	DTA-1-CP027	CP027	CP047
GITR	Mouse	Mouse,IgG2a		in vivo GITR stimulation*	DTA-1-CP028	CP028	BP0085
GITR	Mouse	Mouse,IgG2a	LALA-PG	in vivo GITR stimulation*	DTA-1-CP029	CP029	CP048
GITR	Mouse	Mouse,IgG2b	LALA-PG	in vivo GITR stimulation*	DTA-1-CP031	CP031	CP049
ICOSL	Mouse	Mouse,IgG1	D265A	in vivo ICOSL neutralization*	HK5.3-CP044	CP044	CP047
ICOSL	Mouse	Mouse,IgG2a		in vivo ICOSL neutralization*	HK5.3-CP045	CP045	BP0085

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation | FC Flow cytometry

Antigen	Reactivity	Host / Isotype	Mutation(s)	Application(s)	Clone	Catalog #	lsotype Control
ICOSL	Mouse	Mouse,IgG2a	LALA-PG	in vivo ICOSL neutralization*	HK5.3-CP046	CP046	CP048
LAG-3	Mouse	Mouse,IgG1	D265A	in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, FC*, WB*	C9B7W-CP013	CP013	CP047
LAG-3	Mouse	Mouse,IgG2a		in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, FC*, WB*	C9B7W-CP014	CP014	BP0085
Ly6G	Mouse	Mouse,IgG2a		in vivo neutrophil depletion*, in vivo MDSC depletion*, IF*, IHC-P*, IHC-F*, FC*	1A8-CP129	CP129	BP0085
Ly6G/Ly6C	Mouse	Mouse,IgG2a		in vivo depletion of Gr-1+ myeloid cells*, FC*, IHC-P*, IHC-F*	RB6-8C5-CP135	CP135	BP0085
Ly6G/Ly6C	Mouse	Mouse,IgG2b		in vivo depletion of Gr-1+ myeloid cells*, FC*, IHC-P*, IHC-F*	RB6-8C5-CP172	CP172	BP0086
OX40	Mouse	Mouse,IgG2a		in vivo OX40 activation*, in vitro OX40 activation*, WB*	OX86-CP017	CP017	BP0085
OX40	Mouse	Mouse,IgG2a	LALA-PG	in vivo OX40 activation*, in vitro OX40 activation*, WB*	OX86-CP018	CP018	CP048
PD-1	Mouse	Mouse,IgG1	D265A	in vivo blocking of PD-1/PD-L signaling*	RMP1-14-CP002	CP002	CP047
PD-1		Mouse,IgG1		in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, IHC-F*, IF*, WB*, FC*	29F.1A12™-CP004	CP004	BP0083
PD-1	Mouse	Mouse,IgG1	D265A	in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, IHC-F*, IF*, WB*, FC* $$	29F.1A12™-CP005	CP005	CP047
PD-1	Mouse	Mouse,IgG2a	D265A	in vivo blocking of PD-1/PD-L signaling*	RMP1-14-CP151	CP151	CP150
PD-1	Mouse	Mouse,IgG2a	LALA-PG	in vivo blocking of PD-1/PD-L signaling*	RMP1-14-CP153	CP153	CP150
PD-1	Mouse	Mouse,IgG2a	LALA-PG	in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, IHC-F*, IF*, WB*, FC*	29F.1A12™-CP155	CP155	CP156
PD-1	Mouse	Mouse,IgG2a		in vivo blocking of PD-1/PD-L signaling*	RMP1-14-CP157	CP157	BP0085
PD-1		Mouse,IgG2a		in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, IHC-F*, IF*, WB*, FC* $$	29F.1A12™-CP159	CP159	BP0085
PD-1	Mouse	Mouse,IgG1		in vivo blocking of PD-1/PD-L signaling*	RMP1-14-CP162	CP162	BP0083
PD-1	Mouse	Mouse,IgG1		in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, IHC-F*, IF*, WB*, FC* $$	29F.1A12™-CP178	CP178	BP0083
PD-L1	Mouse	Mouse,IgG1	D265A	in vivo PD-L1 blockade*, IF*, IHC-F*, FC*, WB*	10F.9G2™-CP001	CP001	CP047
PD-L1	Mouse	Mouse,IgG2a	LALA-PG	in vivo PD-L1 blockade*, IF*, IHC-F*, FC*, WB*	10F.9G2™-CP154	CP154	CP048
PD-L1	Mouse	Mouse,IgG2a		in vivo PD-L1 blockade*, IF*, IHC-F*, FC*, WB*	10F.9G2™-CP158	CP158	BP0085
PD-L1	Mouse	Mouse,IgG1		in vivo PD-L1 blockade*, IF*, IHC-F*, FC*, WB*	10F.9G2™-CP168	CP168	BP0083
VEGFR-2	Mouse	Mouse,IgG2a		in vivo blocking of VEGF/VEGFR-2 signaling*, in vitro blocking of VEGFR signaling*, WB*	DC101-CP132	CP132	BP0085

RecombiMAb[™] Isotype Control Antibodies

RecombiMAb[™] isotype control antibodies are recombinantly expressed, ensuring extremely high lot-to-lot consistency and data reproducibility from experiment to experiment. All RecombiMAb[™] antibodies are screened for murine pathogens using ultrasensitive qPCR, screened for protein aggregation, and are guaranteed to contain less than 1 endotoxin unit per milligram.

Product Name	Host / Isotype	Mutation(s)	Clone	Catalog #
Human IgG1 F(ab) isotype control, anti-hen egg lysozyme	Human, IgG1		N/A-CP179	CP179
Human IgG1 (D265A) isotype control, anti-hen egg lysozyme	Human, IgG1	D265A	N/A-CP173	CP173
Human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme	Mouse, IgG2b	K214R, L234F, L235E, P331S	N/A-CP175	CP175
Human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme	Mouse, IgG2a	LALA-PG	N/A-CP149	CP149
Human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus	Human, IgG4	LALA-PG	Palivizumab-CP161	CP161
Human IgG1 (N297A) isotype control, anti-hen egg lysozyme	Mouse, IgG1	N297A	N/A-CP171	CP171
Human IgG1 isotype control, anti-hen egg lysozyme	Human, IgG1		N/A-CP174	CP174
Human IgG1 isotype control, anti-respiratory syncytial virus	Mouse, IgG2a		Palivizumab-CP169	CP169
Human IgG2 isotype control, anti-hen egg lysozyme	Human, IgG4		N/A-CP180	CP180
Human IgG4 (S228P) isotype control, anti-hen egg lysozyme	Human, IgG4	S228P	N/A-CP181	CP181
Human IgG4 (S228P) isotype control, anti-hen egg lysozyme	Mouse, IgG1	S228P	N/A-CP147	CP147
Human IgG4 (S228P) isotype control, anti-respiratory syncytial virus	Human, IgG4	S228P	Palivizumab-CP152	CP152
Human IgG4 (S228P) isotype control, anti-respiratory syncytial virus	Mouse, IgG2a	S228P	Palivizumab-CP152	CP152
Human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme	Human, IgG4	S228P/R409K	N/A-CP183	CP183
Human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme	Mouse, IgG2a	S228P, L235E, P329G (SPLEPG)	N/A-CP148	CP148
Mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme	Human, IgG1	D265A	N/A-CP047	CP047
Mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme	Human, IgG4	D265A	N/A-CP150	CP150
Mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme	Mouse, IgG2a	LALA-PG	N/A-CP048	CP048
Mouse IgG2a (LALA-PG) isotype control, unknown specificity	Mouse, IgG2a	LALA-PG	MOPC-21-CP156	CP156
Mouse IgG2a isotype control, unknown specificity	Mouse, IgG1		MOPC-21-CP160	CP160
Mouse IgG2b (LALA-PG) isotype control, anti-hen egg lysozyme	Mouse, IgG2a	LALA-PG	N/A-CP049	CP049



Don't see a recombinant antibody of your interest? Contact us for more information on recombinant antibody production and transient expression services at: contractservices@bioxcell.com

For the full list of our recombinant antibodies product scan the QR code or visit us at bioxcell.com/recombimab

For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 20,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

